
Navidea Biopharmaceuticals Investor Relations Material
Latest events

EGM 2024
Navidea Biopharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Navidea Biopharmaceuticals Inc
Access all reports
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing precision immunodiagnostic agents and immunotherapeutics. Its primary technology platform, Manocept, is designed to target the CD206 receptor found on activated macrophages, which plays a key role in diagnosing and treating diseases such as cancer, autoimmune conditions, and inflammatory diseases. The company operates through two main segments: Diagnostic Substances, which include imaging agents, and Therapeutic Development Programs, aimed at therapeutic applications of its platform. Navidea is headquartered in Dublin, Ohio, and its shares are traded on the OTC Markets.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
NAVB
Country
🇺🇸 United States